WO2004106327A1 - Process for the preparation of anhydrous eleptritan hemisulphate - Google Patents

Process for the preparation of anhydrous eleptritan hemisulphate Download PDF

Info

Publication number
WO2004106327A1
WO2004106327A1 PCT/IB2004/001694 IB2004001694W WO2004106327A1 WO 2004106327 A1 WO2004106327 A1 WO 2004106327A1 IB 2004001694 W IB2004001694 W IB 2004001694W WO 2004106327 A1 WO2004106327 A1 WO 2004106327A1
Authority
WO
WIPO (PCT)
Prior art keywords
volume
eletriptan
hours
water content
hemisulphate
Prior art date
Application number
PCT/IB2004/001694
Other languages
French (fr)
Inventor
Julian Aranda-Martinez
Catherine Dunne
Juergen Friedrich Kleinschroth
Julie Ann Macrae
Richard Anthony Storey
Ellen Johanna Weilbacher
Original Assignee
Pfizer Limited
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Limited, Pfizer Inc. filed Critical Pfizer Limited
Priority to EP04733602A priority Critical patent/EP1633739A1/en
Priority to CA002527127A priority patent/CA2527127A1/en
Priority to BRPI0410841-8A priority patent/BRPI0410841A/en
Priority to MXPA05012838A priority patent/MXPA05012838A/en
Priority to JP2006530682A priority patent/JP2006528968A/en
Publication of WO2004106327A1 publication Critical patent/WO2004106327A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines

Definitions

  • the present invention relates to an improved process for the preparation of a particular crystalline form of eletriptan hemisulphate.
  • Eletriptan, 3- ⁇ [1 -methylpyrrolidin-2(R)-yl]methyl ⁇ -5-(2-phenylsulfonylethyl)-1 H- indole, and a process for its manufacture, are disclosed in United States Patent number 5,607,951.
  • Eletriptan hemisulphate has the structure of formula (I) below.
  • the hemisulphate salt of mixed morphology is slurried in refluxing tetrahydrofuran (THF), ethanol, isopropanol or industrial methylated spirit (IMS) and then filtered, washed and dried to yield eletriptan hemisulphate form I.
  • THF refluxing tetrahydrofuran
  • IMS industrial methylated spirit
  • a C ⁇ -C 6 alkyl acetate is a compound of the formula CH 3 COOR, wherein R is a C ⁇ -C 6 alkyl group.
  • Preferred solvents are ethyl acetate and n-propyl acetate. Ethyl acetate is particularly preferred.
  • the volume of solvent used, in relation to the weight of eletriptan hemisulphate, is not determinative of success.
  • ethyl acetate is used as the solvent, an amount of from 8 to 12 litres of ethyl acetate per kilogram of eletriptan hemisulphate is preferably employed.
  • the amount of water present in the reaction is crucial to the success of the process and must be no more than 3% volume/volume.
  • the amount of bound water present must be calculated [Karl Fischer (KF) analysis is the most convenient analytical tool] and taken into consideration. If necessary, the starting material can be dried to reduce its water content.
  • the water content of the reaction mixture is preferably from 0.2 to 2% volume/volume, most preferably from 1.3 to 2% volume/volume.
  • those forms of eletriptan that are less resistant to conversion, having a low crystallinity, can be easily converted in a reaction mixture having a lower water content whilst more resistant batches are more conveniently converted in a reaction mixture having a higher water content.
  • the heating should be continued until all the hemisulphate salt present has been converted into the form I polymorph. This will typically take several hours, usually from 4 to 24 hours.
  • the conversion time will depend on the temperature selected, a higher temperature resulting in a lower conversion time.
  • the slurry is heated at from 60 to 80°C. Most preferably, when ethyl acetate is chosen as the solvent, the slurry is heated under reflux.
  • the reaction mixture may also be pressurised to increase the rate of conversion. Differential scanning calorimetry (DSC), performed on a sample taken from the reaction mixture, can be used as a crude indication of how far the conversion has progressed.
  • DSC Differential scanning calorimetry
  • the product can be recovered by filtration. Typically, the reaction mixture is cooled to from 20 to 25°C, filtered, washed with solvent (preferably about 1 litre per kilogram of product) and dried (preferably at 70°C in vacuo). De-lumping may be necessary in certain instances.
  • the average yield of eletriptan hemisulphate form I is 94%.
  • the starting material for the conversion may be amorphous eletriptan hemisulphate, any single polymorphic form of eletriptan hemisulphate, any hydrated/solvated form of either or any mixture of the forgoing, including mixtures comprising form I itself.
  • polymorphic forms of eletriptan hemisulphate that are known are listed below along with characterising data.
  • Polymorphic forms l-XI are known as well as two ethyl acetate solvates XII and XIII and an n-propyl acetate solvate XIV, these solvates containing varying amounts of water.
  • the solvates are readily observed on slurrying amorphous eletriptan hemisulphate in either ethyl acetate or n-propyl acetate, respectively.
  • Form IV is observed when a solution of eletriptan in acetonitrile is treated with dilute sulphuric acid.
  • Powder X-ray diffraction (PXRD) patterns were typically determined using a SIEMENS D5000 powder X-ray diffractometer fitted with an automatic sample changer, a theta-theta goniometer, automatic beam divergence slits, a secondary monochromator and a scintillation counter.
  • the analyses were typically performed with the goniometer running in continuous mode set for a 5 second count per 0.02° step over a two theta range of 2° to 40°.
  • Differential scanning calorimetry was performed using a Perkin Elmerkha Diamond DSC instrument fitted with an automatic sample changer. Approximately 3mg of each sample was accurately weighed into a 50 microlitre aluminium pan and crimp sealed with a perforated lid. The samples were heated at 20°C/minute over the range 30°C to 250°C with a nitrogen gas purge.
  • DSC thermograms for forms III and above have a similar profile with dehydration or desolvation and melt up to ⁇ 140°C then a exothermic recrystallisation event to Form II (Peak at about 186°C) and then a second exothermic recrystallisation event to Form I (Peak at about 226°C).
  • Eletriptan hemisulphate is usually prepared by the reaction of eletriptan free base with sulphuric acid.
  • WO-A-01/23377 describes a process comprising the reaction of eletriptan with concentrated sulphuric acid as a refluxing solution in acetone or as a cooled solution in tetrahydrofuran.
  • a new process for the preparation of eletriptan hemisulphate in a form particularly suitable for further processing to the form I polymorph has been developed.
  • a cooled solution of eletriptan in acetone is treated with dilute aqueous sulphuric acid and the precipitated product is then recovered.
  • the use of dilute sulphuric acid in contrast to the use of concentrated sulphuric acid in the prior art process, is particularly advantageous since it is easier and safer to handle and leads to a cleaner reaction which produces lower levels of by-products.
  • the concentration of the solution of eletriptan in acetone is preferably from 7.5 to 15 litres per kg, most preferably about 10 litres per kg and the solution may advantageously be filtered prior to the addition of the dilute sulphuric acid.
  • the use of from about 0.45 to 0.55 molar equivalents of sulphuric acid per mole of eletriptan produces optimal results and the dilute aqueous sulphuric acid preferably contains about 0.2 kg/litre of sulphuric acid.
  • the reaction is preferably carried out at a temperature of from -5°C to +5°C and a gradual addition (for instance, over a period of 1 to 2 hours) of sulphuric acid is preferred.
  • the product may conveniently be recovered by granulation (preferably at a temperature of from -5°C to +5°C, over a period of about 2 hours), filtration, washing with further acetone (preferably two portions of approximately 0.5 litres per kg of product) and drying (preferably at about 50°C, in vacuo).
  • the product of this process after drying, is typically a mixture of several hydrated, hygroscopic forms of variable water and acetone content (usually about 1.5 to 6% weight/weight water by Karl Fischer analysis). Forms III, V, VI, VIII and XI have been observed - see the experimental section below for details. Before conversion to the form I polymorph, using the process described above, the product is dried, if necessary, until its water content is no more than 6% weight/weight.
  • Differential scanning calorimetry (DSC) was performed using a Mettler-Toledo DSC 822e instrument. The samples were heated at 10°C/minute over the range 30°C to 300°C.
  • Infra-red (IR) analysis was performed using a Bruker-Optics Vector 22 instrument. The sample was prepared using Golden- Gate ATR technology. Only characteristic peaks are listed.
  • Example 1 Powder X-ray diffraction
  • the precipitate was recovered by filtration and washed with acetone (2 x 50 ml). After standing at ambient temperature for 2 hours, 10 g of the product (total weight 119.4 g), contaminated with water and acetone (water by K.F., 8.22 %; acetone by GC -1.85 %), was removed for investigation.
  • the precipitate was recovered by filtration, washed with acetone (2 x 35 ml) and dried at 50°C for 16 hours in a forced air dryer to yield eletriptan hemisulphate (80.9 g, 94 %) as a white solid (water by K.F., 1.43 %; acetone by GC, 0.06 %).
  • DSC 129 °C endo, 135 °C exo, 171 °C endo, 182 °C exo, 221 °C endo
  • the precipitate was recovered by filtration, washed with acetone (2 x 50 ml) and dried at 50°C for 15 hours in a forced air dryer to yield eletriptan hemisulphate (111.5 g, 96 %, 99.84% pure by HPLC) as an off-white solid (water by K.F., 2.94 %; acetone by GC, 1.3 %).
  • DSC 116 °C endo, 120 °C exo, 150 °C exo, 179 °C endo, 223 °C endo
  • the precipitate was recovered by filtration and dried at 50°C for 10 hours in a forced air dryer to yield eletriptan hemisulphate (22.1 g, 93 %, 99.89% pure by HPLC) as an off-white solid (water by K.F., 5.04 %).
  • the precipitate was recovered by filtration and dried at 50°C for 10 hours in a forced air dryer to yield eletriptan hemisulphate (18.0 g, 77 %, 99.89% pure by HPLC) as an off-white solid (water by K.F., 5.32%).
  • the precipitate was recovered by filtration, washed with acetone (2 x 50 ml) and dried at 50°C for 14 hours in a forced air dryer to yield eletriptan hemisulphate (110.4 g, 96 %, 99.86% pure by HPLC) as an off-white solid (water by K.F., 3.04 %; acetone by GC, 0.01 %).
  • a suspension of eletriptan hemisulphate (the hydrated form III product of Example 4, 5 g) in a mixture of ethyl acetate (50 ml) containing 0.45% volume/volume water was heated under reflux for 24 hours (total water content was 0.95 % volume/volume).
  • a portion of the solvent (10 ml, 20 % of the volume) was removed by azeotropic distillation. After cooling to ambient temperature, the precipitate was recovered by filtration, washed with ethyl acetate (5 ml) and dried at 70°C for 15 hours to yield eletriptan hemisulphate form I polymorph (4.7 g, 93 %, 99.79% pure by HPLC) as a white solid.
  • a suspension of eletriptan hemisulphate (the product of Example 5, 5 g) in a ethyl acetate (50 ml) containing 0.45% volume/volume water was heated under- reflux for 24 hours (total water content was 1 % volume/volume).
  • a portion of the solvent (10 ml, 20 % of the volume) was removed by azeotropic distillation. After cooling to ambient temperature, the precipitate was recovered by filtration, washed with ethyl acetate (5 ml) and dried at 70°C for 15 hours to yield eletriptan hemisulphate form I polymorph (4.7 g, 93 %, 99.84% pure by HPLC) as a white solid.
  • a suspension of eletriptan hemisulphate (the hydrated form III product of Example 7, 2.5 g) in a mixture of ethyl acetate (25 ml) containing 0.3% volume/volume water was heated under reflux for 24 hours (total water content was 0.6 % volume/volume).
  • a portion of the solvent (5 ml, 20 % of the volume) was removed by azeotropic distillation. After cooling to ambient temperature, the precipitate was recovered by filtration, washed with ethyl acetate (2.5 ml) and dried at 70°C for 4 hours to yield eletriptan hemisulphate form I polymorph (2.1 g, 88 %) as a white solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention provides an improved process for the preparation of a polymorph of eletriptan hemisulphate of formula (I).

Description

ROCESS FOR THE PREPARATION OF ANHYDROUS ELEPTRITAN HEMISULPHATE
The present invention relates to an improved process for the preparation of a particular crystalline form of eletriptan hemisulphate.
Eletriptan, 3-{[1 -methylpyrrolidin-2(R)-yl]methyl}-5-(2-phenylsulfonylethyl)-1 H- indole, and a process for its manufacture, are disclosed in United States Patent number 5,607,951.
Eletriptan hemisulphate has the structure of formula (I) below.
Figure imgf000003_0001
International patent application number PCT/EP95/01914, published as WO-A- 96/06842, discloses two crystalline forms of eletriptan hemisulphate. The first, designated the α-form, is characterised as having a melting point of 185°C. This form will be referred to below as eletriptan hemisulphate form II. The second, designated the β-form, is characterised as having a melting point of 145-147°C and will be referred to below as eletriptan hemisulphate form III.
International patent application number PCT/EP98/04176, published as WO-A- 99/01135, describes a process for making eletriptan hemisulphate form III.
International patent application number PCT/I BOO/01305, published as WO-A- 01/23377, discloses a further crystalline form of eletriptan hemisulphate. This polymorph, which will be referred to below as eletriptan hemisulphate form I, is characterised by its DSC melting point of 226°C and other data such as its powder X-ray diffraction (PXRD) pattern. Also disclosed are several processes for preparing eletriptan hemisulphate form I, both from eletriptan itself and from eletriptan hemisulphate of mixed morphology (i.e. existing at least partly in one or more other polymorphic forms). In the latter case, the hemisulphate salt of mixed morphology is slurried in refluxing tetrahydrofuran (THF), ethanol, isopropanol or industrial methylated spirit (IMS) and then filtered, washed and dried to yield eletriptan hemisulphate form I.
These processes for preparing eletriptan hemisulphate form I have proven to be unsatisfactory, especially on a large scale, and do not give the form I polymorph reliably. For instance, in the case where THF is used as the solvent, the product is often obtained contaminated with solvated/hydrated forms (particularly hydrates). Such undesired forms are obtained in an unpredictable fashion.
It will be appreciated that in the large scale preparation of a drug molecule it is essential to establish a process that is robust in the sense of reliably producing a homogeneous product containing the same crystalline form, free of other crystalline forms and solvates.
There is thus a need to provide a high-yielding and robust process for the preparation of eletriptan hemisulphate form I which can be carried out reliably on a large scale.
It has now been surprisingly found that it is possible to prepare eletriptan hemisulphate form I in a reliable and high-yielding manner. In the new process, a stirred suspension of any other form of eletriptan hemisulphate (or any mixture of forms) in a d-C6 alkyl acetate solvent is heated and then concentrated by azeotropic distillation prior to recovery of the product.
A Cι-C6 alkyl acetate is a compound of the formula CH3COOR, wherein R is a Cι-C6 alkyl group. Preferred solvents are ethyl acetate and n-propyl acetate. Ethyl acetate is particularly preferred.
The volume of solvent used, in relation to the weight of eletriptan hemisulphate, is not determinative of success. Where ethyl acetate is used as the solvent, an amount of from 8 to 12 litres of ethyl acetate per kilogram of eletriptan hemisulphate is preferably employed.
However, the amount of water present in the reaction is crucial to the success of the process and must be no more than 3% volume/volume. In the case where the hemisulphate starting material is hydrated, the amount of bound water present must be calculated [Karl Fischer (KF) analysis is the most convenient analytical tool] and taken into consideration. If necessary, the starting material can be dried to reduce its water content. The water content of the reaction mixture is preferably from 0.2 to 2% volume/volume, most preferably from 1.3 to 2% volume/volume.
In general, those forms of eletriptan that are less resistant to conversion, having a low crystallinity, can be easily converted in a reaction mixture having a lower water content whilst more resistant batches are more conveniently converted in a reaction mixture having a higher water content.
The heating should be continued until all the hemisulphate salt present has been converted into the form I polymorph. This will typically take several hours, usually from 4 to 24 hours. The conversion time will depend on the temperature selected, a higher temperature resulting in a lower conversion time. Preferably, the slurry is heated at from 60 to 80°C. Most preferably, when ethyl acetate is chosen as the solvent, the slurry is heated under reflux. The reaction mixture may also be pressurised to increase the rate of conversion. Differential scanning calorimetry (DSC), performed on a sample taken from the reaction mixture, can be used as a crude indication of how far the conversion has progressed.
When the conversion is complete, a portion of the solvent must, if necessary, be removed by azeotropic distillation until the water content of the reaction mixture has fallen to below 1% volume/volume. This step is important in order to avoid the later formation of any solvates of the product at ambient temperature. For instance, where about 10 litres of ethyl acetate per kg of eletriptan hemisulphate starting material has been used, it is usually sufficient to distil off from one to two fifths of the volume added. Occasionally, if the conversion is slow, it is advantageous to carry out the azeotropic distillation during the conversion rather than after the conversion. In this case, the water content of the reaction mixture should be reduced to below.. 0.3% volume/volume, fresh, dry solvent should be added and the reaction should be heated under reflux for a further period.
The product can be recovered by filtration. Typically, the reaction mixture is cooled to from 20 to 25°C, filtered, washed with solvent (preferably about 1 litre per kilogram of product) and dried (preferably at 70°C in vacuo). De-lumping may be necessary in certain instances.
The average yield of eletriptan hemisulphate form I is 94%.
In principle, the starting material for the conversion may be amorphous eletriptan hemisulphate, any single polymorphic form of eletriptan hemisulphate, any hydrated/solvated form of either or any mixture of the forgoing, including mixtures comprising form I itself.
The polymorphic forms of eletriptan hemisulphate that are known are listed below along with characterising data. Polymorphic forms l-XI are known as well as two ethyl acetate solvates XII and XIII and an n-propyl acetate solvate XIV, these solvates containing varying amounts of water. The solvates are readily observed on slurrying amorphous eletriptan hemisulphate in either ethyl acetate or n-propyl acetate, respectively. Form IV is observed when a solution of eletriptan in acetonitrile is treated with dilute sulphuric acid.
Powder X-ray diffraction (PXRD) patterns were typically determined using a SIEMENS D5000 powder X-ray diffractometer fitted with an automatic sample changer, a theta-theta goniometer, automatic beam divergence slits, a secondary monochromator and a scintillation counter. The samples were prepared for analysis by packing the powder on to silicon wafer specimen mounts. Each specimen was rotated whilst being irradiated with copper K-alphai X-rays (wavelength = 1.5406 A) with the X-ray tube operated at 40kV/40mA. The analyses were typically performed with the goniometer running in continuous mode set for a 5 second count per 0.02° step over a two theta range of 2° to 40°. Differential scanning calorimetry (DSC) was performed using a Perkin Elmer„ Diamond DSC instrument fitted with an automatic sample changer. Approximately 3mg of each sample was accurately weighed into a 50 microlitre aluminium pan and crimp sealed with a perforated lid. The samples were heated at 20°C/minute over the range 30°C to 250°C with a nitrogen gas purge. DSC thermograms for forms III and above have a similar profile with dehydration or desolvation and melt up to ~140°C then a exothermic recrystallisation event to Form II (Peak at about 186°C) and then a second exothermic recrystallisation event to Form I (Peak at about 226°C).
FORM I PXRD See Figure 1a
The characteristic peaks are:
Figure imgf000007_0001
DSC See Figure 1b (226 °C, endotherm). FORM il
PXRD See Figure 2
The characteristic peaks are:
Figure imgf000008_0001
DSC 186°C, endotherm.
FORM III
PXRD See Figure 3a
The characteristic peaks are:
Figure imgf000008_0002
DSC See Figure 3b (148°C, 187°C, 226 °C, all endotherm). FORM IV
PXRD See Figure 4
The characteristic peaks are:
Figure imgf000009_0001
FORM V PXRD See Figure 5a
The characteristic peaks are:
Figure imgf000009_0002
DSC See Figure 5b (153°C, 189°C, 227 °C, all endotherm). FORM VI
PXRD See Figure 6a
The characteristic peaks are:
Figure imgf000010_0001
DSC See Figure 6b (149°C, 186°C, 226 °C, all endotherm).
FORM VII
PXRD See Figure 7
The characteristic peaks are:
Figure imgf000010_0002
FORM VIII
PXRD See Figure 8
The characteristic peaks are:
Figure imgf000011_0001
FORM IX
PXRD See Figure 9
The characteristic peaks are:
Figure imgf000011_0002
FORM X
PXRD See Figure 10
The characteristic peaks are:
Figure imgf000012_0001
FORM XI
PXRD See Figure 11
The characteristic peaks are:
Figure imgf000012_0002
FORM XII (EtOAc solvate 1) PXRD See Figure 12a
The characteristic peaks are:
Figure imgf000013_0001
DSC See Figure 12b (146°C, 186°C, 226 °C, all endotherm).
FORM XIII (EtOAc solvate 2) PXRD See Figure 13
The characteristic peaks are:
Figure imgf000013_0002
FORM XIV (n-PrOAc solvate) PXRD See Figure 14
The characteristic peaks are:
Figure imgf000014_0001
Forms III, V, VI and XI interchange, according to the prevailing relative humidity.
Eletriptan hemisulphate is usually prepared by the reaction of eletriptan free base with sulphuric acid. For instance, WO-A-01/23377 describes a process comprising the reaction of eletriptan with concentrated sulphuric acid as a refluxing solution in acetone or as a cooled solution in tetrahydrofuran. As a further aspect of the present invention, a new process for the preparation of eletriptan hemisulphate in a form particularly suitable for further processing to the form I polymorph has been developed.
In the new process, a cooled solution of eletriptan in acetone is treated with dilute aqueous sulphuric acid and the precipitated product is then recovered. The use of dilute sulphuric acid, in contrast to the use of concentrated sulphuric acid in the prior art process, is particularly advantageous since it is easier and safer to handle and leads to a cleaner reaction which produces lower levels of by-products. The concentration of the solution of eletriptan in acetone is preferably from 7.5 to 15 litres per kg, most preferably about 10 litres per kg and the solution may advantageously be filtered prior to the addition of the dilute sulphuric acid. The use of from about 0.45 to 0.55 molar equivalents of sulphuric acid per mole of eletriptan produces optimal results and the dilute aqueous sulphuric acid preferably contains about 0.2 kg/litre of sulphuric acid. The reaction is preferably carried out at a temperature of from -5°C to +5°C and a gradual addition (for instance, over a period of 1 to 2 hours) of sulphuric acid is preferred. The product may conveniently be recovered by granulation (preferably at a temperature of from -5°C to +5°C, over a period of about 2 hours), filtration, washing with further acetone (preferably two portions of approximately 0.5 litres per kg of product) and drying (preferably at about 50°C, in vacuo).
The product of this process, after drying, is typically a mixture of several hydrated, hygroscopic forms of variable water and acetone content (usually about 1.5 to 6% weight/weight water by Karl Fischer analysis). Forms III, V, VI, VIII and XI have been observed - see the experimental section below for details. Before conversion to the form I polymorph, using the process described above, the product is dried, if necessary, until its water content is no more than 6% weight/weight.
The following Examples illustrate the invention. Powder X-ray diffraction (PXRD) patterns were determined using a STOE STADI-P powder X-ray diffractometer. Each specimen was rotated whilst being irradiated with copper K-alphat X-rays (wavelength = 1.5406 A). The analyses were performed with the goniometer running in transmission mode set for a 7 second count per 0.02° step over a two theta range of 4° to 56°. Only characteristic peaks are listed with relative intensity in brackets. Differential scanning calorimetry (DSC) was performed using a Mettler-Toledo DSC 822e instrument. The samples were heated at 10°C/minute over the range 30°C to 300°C. Infra-red (IR) analysis was performed using a Bruker-Optics Vector 22 instrument. The sample was prepared using Golden- Gate ATR technology. Only characteristic peaks are listed. Example 1
A solution of eletriptan (100 g, 0.26 mol) in acetone (955 ml) was filtered and the filter was rinsed with further acetone (45 ml). The clear yellow solution obtained. was cooled to 0°C and dilute aqueous sulphuric acid (77 g of a 1 :5 weight/weight mixture of 96 % cone, sulphuric acid:water, 0.126 mol, 0.48 equivalents) was added with stirring, maintaining a temperature of from -5°C to +5°C. The addition took place over a period of 1 hour. The resulting suspension was granulated by stirring for a further 2 hours at 0°C. The precipitate was recovered by filtration and washed with acetone (2 x 50 ml). After standing at ambient temperature for 2 hours, 10 g of the product (total weight 119.4 g), contaminated with water and acetone (water by K.F., 8.22 %; acetone by GC -1.85 %), was removed for investigation.
DSC: 70 °C endo, 96 °C endo, 131 °C exo, 165 °C endo, 224 °C endo
PXRD: 5.6 (10), 6.79 (12), 10.33 (30), 11.83 (74), 12.21 (24), 13.15 (24),
13.57 (24), 14.55 (24), 15.61 (21), 16.01 (72), 16.57 (31), 23.43
(100) IR: 3581 , 3400-2200, 1710, 1479, 1295, 1138, 1037, 688, 597
Assigned as a mixture of form III and an acetone solvate.
The remaining amount was dried at 50°C for 15 hours in a forced air dryer to yield eletriptan hemisulphate (100.2 g, 95 %) as an off-white solid (water by K.F., 1.93 %; acetone by GC, < 0.04 %).
DSC: 125 °C endo, 132 °C exo, 172 °C endo, 218 °C endo
PXRD: 5.67 (21), 6.85 (8), 7.83 (10), 10.4 (10), 10.88 (19), 11.37 (15),
11.89 (41), 12.61 (27), 12.91 (51), 13.63 (31), 14.85 (24), 15.89 (60), 16.39 (37), 17.07 (31), 17.65 (48), 18.29 (57), 22.15 (100)
IR: 3590, 3400-2200, 1480, 1293, 1139, 1024, 686, 598 '
Assigned as form VI. A portion of this material (50.1 g) was further dried at 70°C for 15 hours in a forced air dryer to yield 50.1 g of an off-white solid (water by K.F., 2.53 %; acetone by GC, < 0.01 %).
DSC: 119 °C endo, 125 °C exo, 164 °C endo, 173 °C exo, 209 °C endo,
222 °C endo PXRD: 5.67 (21), 6.85 (8), 7.83 (10), 10.4 (10), 10.88 (19), 11.37 (15),
11.89 (41), 12.61 (27), 12.91 (51), 13.63 (31), 14.85 (24), 15.89 (60), 16.39 (37), 17.07 (31), 17.65 (48), 18.29 (57), 22.15 (100)
IR: 3590, 3400-2200, 1479, 1293, 1139, 1025, 686, 598
Assigned as a mixture of forms III and VI.
Example 2
A solution of eletriptan (75 g, 196 mmol) in acetone (715 ml) was filtered and the filter was rinsed with further acetone (35 ml). The clear yellow solution obtained was cooled to 0°C and dilute aqueous sulphuric acid (58 g of a 1 :5 weight/weight mixture of 96 % cone, sulphuric acid:water, 95 mmol, 0.47 equivalents) was added, with stirring, maintaining the temperature at from -5°C to +5°C. The addition took place over a period of 45 minutes. The resulting suspension was granulated by stirring for a further 2 hours at 0°C. The precipitate was recovered by filtration, washed with acetone (2 x 35 ml) and dried at 50°C for 16 hours in a forced air dryer to yield eletriptan hemisulphate (80.9 g, 94 %) as a white solid (water by K.F., 1.43 %; acetone by GC, 0.06 %).
DSC: 129 °C endo, 135 °C exo, 171 °C endo, 182 °C exo, 221 °C endo
PXRD: 5.71 (19), 7.91 (6), 10.91 (20), 11.41 (8), 11.89 (31), 12.93 (87), 13.65 (13), 13.87 (10), 14.45 (15), 14.85 (23), 15.37 (16), 15.91
(51), 22.19 (100) IR: 3590, 3400-2200, 1480, 1293, 1139, 1024, 686, 598 Assigned as form VI.
Example 3
A solution of eletriptan (100 g, 0.26 mol) in acetone (955 ml) was filtered and the filter was rinsed with further acetone (45 ml). The clear yellow solution obtained was cooled to 0°C and dilute aqueous sulphuric acid (77 g of a 1 :5 weight/weight mixture of 96 % cone, sulphuric acid:water, 0.126 mol, 0.48 equivalents) was added with stirring, maintaining the temperature at from -5°C to +5°C. The addition took place over a period of 1 hour. The resulting suspension was granulated by stirring for another 2 hours at 0°C. The precipitate was recovered by filtration, washed with acetone (2 x 50 ml) and dried at 50°C for 15 hours in a forced air dryer to yield eletriptan hemisulphate (111.5 g, 96 %, 99.84% pure by HPLC) as an off-white solid (water by K.F., 2.94 %; acetone by GC, 1.3 %).
DSC: 116 °C endo, 120 °C exo, 150 °C exo, 179 °C endo, 223 °C endo
PXRD: 5.55 (52), 6.85 (43), 7.43 (25), 10.47 (27), 11.11 (22), 11.91 (73),
13.55 (53), 14.53 (25), 16.19 (94), 16.59 (26), 17.03 (53), 17.65 (48), 18.43 (54), 23.45 (100) IR: 3591 , 3400-2200, 1710, 1480, 1302, 1138, 1024, 687, 600
Assigned as form VIII.
Example 4
A solution of eletriptan (20 g, 52.3 mmol) in acetone (200 ml) was filtered. The resulting clear yellow solution was cooled to 0°C and dilute aqueous sulphuric acid (15.1 g of a 1 :5 weight/weight mixture of 96 % cone, sulphuric acid:water, 24.6 mmol, 0.47 equivalents) was added with stirring, maintaining the temperature at from -5°C to +5°C. The addition took place over a period of 2 hours. The resulting suspension was granulated by stirring for a further 2 hours at 0°C. The precipitate was recovered by filtration and dried at 50°C for 10 hours in a forced air dryer to yield eletriptan hemisulphate (22.1 g, 93 %, 99.89% pure by HPLC) as an off-white solid (water by K.F., 5.04 %).
PXRD: 5.67 (10), 6.77 (10), 10.24 (15), 11.87 (66), 13.07 (21), 13.57 (43), 14.49 (35), 16.07 (91), 17.53 (23), 18.27 (23), 23.43 (100)
Assigned as form III.
Example 5
A solution of eletriptan (20 g, 52.3 mmol) in acetone (200 ml) was filtered. The resulting clear yellow solution was cooled to 0°C and dilute sulphuric acid (18.5 g of a 1 :5 weight/weight mixture of 96 % cone, sulphuric acid:water, 30.2 mmol, 0.58 equivalents) was added with stirring at a temperature of from -5°C to +5°C. The addition took place over a period of 2 hours. The resulting suspension was granulated by stirring for a further 2 hours at 0°C. The precipitate was recovered by filtration and dried at 50°C for 10 hours in a forced air dryer to yield eletriptan hemisulphate (18.0 g, 77 %, 99.89% pure by HPLC) as an off-white solid (water by K.F., 5.32%).
Example 6
A solution of eletriptan (66.3 g, 166 mmol) in acetone (633 ml) was filtered and the filter was rinsed with further acetone (30 ml). The resulting clear yellow solution was cooled to 0°C and dilute aqueous sulphuric acid (51 g of a 1 :5 weight/weight mixture of 96 % cone, sulphuric acid:water, 83 mmol, 0.5 equivalents) was added, with stirring, at a temperature of from at -5°C to +5°C. The addition took place over a period of 55 minutes. The resulting suspension was granulated by stirred for a further 3 hours at 0°C. After standing overnight at ambient temperature, the precipitate was recovered by filtration, washed with acetone (2 x 33 ml) and dried at 50°C for 7 hours in a forced air dryer to yield eletriptan hemisulphate (70.5 g, 94 %) as a white solid (water by K.F., 2.6 %; acetone by GC, < 0.01 %). DSC: 121 °C endo, 126 °C exo, 167 °C endo
PXRD: 5.67 (10), 6.77 (10), 10.24 (15), 11.87 (66), 13.07 (21), 13.57 (43),
14.49 (35), 16.07 (91), 17.53 (23), 18.27 (23), 23.43 (100) IR: 3582, 3400-2200, 1479, 1302, 1151 , 1036, 687, 601
Assigned as form III.
A sample of the product (10 g) of was further dried at 70°C for 3 hours to give a white solid (9.91 g, water by K.F., 1.99%).
DSC: 132 °C endo, 139 °C exo, 175 °C endo, 185 °C endo
PXRD: 5.69 (30), 6.8 (5), 7.86 (10), 10.89 (21), 11.85 (59), 12.57 (36),
12.89 (69), 15.89 (85), 17.47 (62), 18.29 (81), 18.95 (65), 22.13 (100)
IR: 3589, 3400-2200, 1480, 1304, 1149, 1037, 690, 620
Assigned as form VI.
Example 7
A solution of eletriptan (100 g, 0.26 mol) in acetone (955 ml) was filtered and the filter was rinsed with further acetone (45 ml). The resulting clear yellow solution was cooled to 0°C and dilute aqueous sulphuric acid (77 g of a 1 :5 weight/weight mixture of 96 % cone, sulphuric acid:water, 0.126 mol, 0.48 equivalents) was added with stirring at a temperature of from -5°C to +5°C. The addition took place over a period of 55 min. The resulting suspension was granulated by stirring for a further 2 hours at 0°C. The precipitate was recovered by filtration, washed with acetone (2 x 50 ml) and dried at 50°C for 14 hours in a forced air dryer to yield eletriptan hemisulphate (110.4 g, 96 %, 99.86% pure by HPLC) as an off-white solid (water by K.F., 3.04 %; acetone by GC, 0.01 %).
DSC: 117 °C endo, 169 °C endo, 205 °C endo, 222 °C endo PXRD: 5.65 (22), 6 (10), 10.28 (19), 10.49 (15), 11.89 (70), 12.93 (30),
13.57 (43), 14.55 (44), 16.13 (91), 17.07 (61), 17.53 (35), 18.35 (63), 23.47 (100)
IR: 3590, 3400-2200, 1479, 1302, 1138, 1025, 687, 589
Assigned as form III.
Example 8
A suspension of eletriptan hemisulphate (hydrated form VI from Example 1 , 10 g) in a mixture of ethyl acetate (100 ml) and water (1 ml) was heated under reflux, with stirring, for 16 hours (total water content ~ 1.2 % volume/volume). A portion of the solvent (40 ml, 40 % of the volume) was removed by azeotropic distillation and fresh, dry ethyl acetate (40 ml) was added. The suspension was heated under reflux for a further 6 hours. After cooling to ambient temperature, the precipitate was recovered by filtration, washed with ethyl acetate (10 ml) and dried at 70°C for 7 hours to yield eletriptan hemisulphate form I polymorph (9.36 g, 94 %) as a white solid.
DSC: 223 °C endo
IR: 3400-2200, 1480, 1302, 1133, 1006, 690, 603
Example 9
A suspension of eletriptan hemisulphate (the hydrated product of Example 2, 10 g) in a mixture of ethyl acetate (100 ml) and water (1.5 ml) was heated under reflux, with stirring, for 16 hours (total water content ~ 1.65 % volume/volume). A portion of the solvent (40 ml, 40 % of the volume) was removed by azeotropic distillation and fresh, dry ethyl acetate (40 ml) was added. The suspension was heated under reflux for a further 6 hours. After cooling to ambient temperature (over 30 minutes), the precipitate was recovered by filtration, washed with ethyl acetate (10 ml) and dried at 70°C for 3 hours to yield eletriptan hemisulphate form I polymorph (9.38 g, 94 %) as an off-white solid. DSC: 223°C endo
IR: 3400-2200, 1480, 1302, 1133, 1006, 690, 603
Example 10
A suspension of eletriptan hemisulphate (the hydrated form VIII product of Example 3, 2.5 g) in a mixture of ethyl acetate (25 ml) containing 1.7% volume/volume water was heated under reflux for 24 hours (total water content 2 % volume/volume). A portion of the solvent (5 ml, 20 % of the volume) was removed by azeotropic distillation. After cooling to ambient temperature, the precipitate was recovered by filtration, washed with ethyl acetate (2.5 ml) and dried at 70°C for 4 hours to yield eletriptan hemisulphate form I polymorph (2.22 g, 93 %) as a white solid.
DSC: 222 °C endo
Example 11
A suspension of eletriptan hemisulphate (the hydrated form III product of Example 4, 5 g) in a mixture of ethyl acetate (50 ml) containing 0.45% volume/volume water was heated under reflux for 24 hours (total water content was 0.95 % volume/volume). A portion of the solvent (10 ml, 20 % of the volume) was removed by azeotropic distillation. After cooling to ambient temperature, the precipitate was recovered by filtration, washed with ethyl acetate (5 ml) and dried at 70°C for 15 hours to yield eletriptan hemisulphate form I polymorph (4.7 g, 93 %, 99.79% pure by HPLC) as a white solid.
DSC: 223 °C endo Example 12
A suspension of eletriptan hemisulphate (the product of Example 5, 5 g) in a ethyl acetate (50 ml) containing 0.45% volume/volume water was heated under- reflux for 24 hours (total water content was 1 % volume/volume). A portion of the solvent (10 ml, 20 % of the volume) was removed by azeotropic distillation. After cooling to ambient temperature, the precipitate was recovered by filtration, washed with ethyl acetate (5 ml) and dried at 70°C for 15 hours to yield eletriptan hemisulphate form I polymorph (4.7 g, 93 %, 99.84% pure by HPLC) as a white solid.
DSC: 222 °C endo
PXRD: 7.37 (21), 9.27 (25), 10.37 (43), 11.35 (34), 12.35 (35), 16.81 (73),
17.47 (54), 17.93 (55), 18.67 (34), 19.43 (25), 21.39 (100)
Example 13
A suspension of eletriptan hemisulphate (the hydrated forms III and V product of Example 6, 2.5 g) in ethyl acetate (25 ml) was heated under reflux for 4 hours (total water content was 0.26 % volume/volume). After cooling to ambient temperature, the precipitate was recovered by filtration, washed with ethyl acetate (5 ml) and dried at 70°C for 7 hours to yield eletriptan hemisulphate form I polymorph (2.1 g, 85 %) as a white solid.
DSC: 222 °C endo
Example 14
A suspension of eletriptan hemisulphate (the hydrated form VI product of Example 6, 2.5 g) in ethyl acetate (25 ml) was heated under reflux for 24 hours
(total water content was 0.2 % volume/volume). After cooling to ambient temperature, the precipitate was recovered by filtration, washed with ethyl acetate (5 ml) and dried at 70°C for 7 hours to yield eletriptan hemisulphate form I polymorph (2.2 g, 89 %) as a white solid.
Example 15
A suspension of eletriptan hemisulphate (the hydrated form III product of Example 7, 2.5 g) in a mixture of ethyl acetate (25 ml) containing 0.3% volume/volume water was heated under reflux for 24 hours (total water content was 0.6 % volume/volume). A portion of the solvent (5 ml, 20 % of the volume) was removed by azeotropic distillation. After cooling to ambient temperature, the precipitate was recovered by filtration, washed with ethyl acetate (2.5 ml) and dried at 70°C for 4 hours to yield eletriptan hemisulphate form I polymorph (2.1 g, 88 %) as a white solid.
DSC: 223 °C endo
Example 16
A suspension of eletriptan hemisulphate (with a high water content (~ 9 %) and acetone content (~ 6.4 %), 10 g) in a mixture of ethyl acetate (100 ml) and water (0.6 ml) was heated under reflux for 16 hours (total water content was about 1.5 % volume/volume). A portion of the solvent (40 ml, 40 % of the volume) was removed by azeotropic distillation and fresh, dry ethyl acetate (40 ml) was added. The reaction mixture was heated under reflux for a further 6 hours. After cooling to ambient temperature (over 30 minutes), the precipitate was recovered by filtration, washed with ethyl acetate (10 ml) and dried at 70°C for 2.5 hours to yield eletriptan hemisulphate form I polymorph (8.2 g, 96 %) as an off-white solid.
DSC: 223 °C endo Example 17
A suspension of eletriptan hemisulphate (with a water content of 5.23 % and acetone content of less than 50ppm, 10 g) in a mixture of ethyl acetate (100 ml) and water (1 ml) was heated under reflux for 16 hours (total water content was about 1.5 % volume/volume). A portion of the solvent (40 ml, 40 % of the volume) was removed by azeotropic distillation and fresh, dry ethyl acetate (40 ml) was added. The reaction mixture was heated under reflux for a further 6 hours. After cooling to ambient temperature (over 20 minutes), the precipitate was recovered by filtration, washed with ethyl acetate (10 ml) and dried at 70°C for 3 hours to yield eletriptan hemisulphate form I polymorph (9.1 g, 96 %) as an off-white solid.
DSC: 222 °C endo
Example 18
A suspension of eletriptan hemisulphate (mainly hydrated form VI, water content 2.33 %, 10 g) in a mixture of ethyl acetate (100 ml) and water (1 ml) was heated under reflux for 16 hours (total water content was about 1.3 % volume/volume). A portion of the solvent (40 ml, 40 % of the volume) was removed by azeotropic distillation and fresh, dry ethyl acetate (40 ml) was added. The reaction mixture was heated under reflux for a further 6 hours. After cooling to ambient temperature (over 20 minutes), the precipitate was recovered by filtration, washed with ethyl acetate (10 ml) and dried at 70°C to yield eletriptan hemisulphate form I polymorph (9 g, 92 %) as an off-white solid.
DSC: 224 °C endo
IR: 3400-2200, 1480, 1302, 1133, 1006, 690, 604

Claims

Claims
1. A process for preparing anhydrous eletriptan hemisulphate form I polymorph characterised by a powder X-ray diffraction pattern obtained using copper K-alphai radiation (λ = 0.15046nm) which shows main peaks at 9.28, 10.38, 11.37, 12.40, 16.84, 17.46, 17.53, 17.78, 17.98, 19.48, 20.70, 21.29, 21.45, 22.21 , 22.64, 23.08, 25.20 and 25.79, comprising the steps of (a) slurrying any other form of eletriptan hemisulphate in a solvent of the formula CH3COOR, wherein R is a CrC6 alkyl group; (b) adjusting the water content of the slurry, if necessary, to 3% volume/volume or less; (c) heating the slurry; (d) concentrating the reaction mixture by azeotropic distillation, if necessary, until the water content of the reaction mixture has fallen to below 1% volume/volume; and (e) recovering the product.
2. A process as claimed in claim 1 wherein the solvent is ethyl acetate or n- propyl acetate.
3. A process as claimed in claim 2 wherein the solvent is ethyl acetate.
4. A process as claimed in any one of the preceding claims wherein in step
(b) the water content is adjusted to from 0.2 to 2% volume/volume.
5. A process as claimed in claim 4 wherein the water content is adjusted to from 1.3 to 2% volume/volume.
6. A process as claimed in any one of the preceding claims wherein in step
(c) the slurry is heated at from 60 to 80°C.
7. A process as claimed in claim 3 wherein in step (c) the slurry is heated under reflux.
8. A process as claimed in any one of the preceding claims wherein in step
(d) the water content is adjusted to below 0.3% volume/volume.
9. A process as claimed in claim 8 wherein step (d) is performed during the course of step (c) rather than following it.
10. A process according to any one of the preceding claims wherein the starting material is prepared by reacting a solution of eletriptan in acetone with dilute aqueous sulphuric acid.
PCT/IB2004/001694 2003-05-30 2004-05-18 Process for the preparation of anhydrous eleptritan hemisulphate WO2004106327A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP04733602A EP1633739A1 (en) 2003-05-30 2004-05-18 Process for the preparation of anhydrous eleptritan hemisulphate
CA002527127A CA2527127A1 (en) 2003-05-30 2004-05-18 Process for the preparation of anhydrous eletriptan hemisulphate
BRPI0410841-8A BRPI0410841A (en) 2003-05-30 2004-05-18 Process for the preparation of anhydrous electriptan hemisulfate
MXPA05012838A MXPA05012838A (en) 2003-05-30 2004-05-18 Process for the preparation of anhydrous eleptritan hemisulphate.
JP2006530682A JP2006528968A (en) 2003-05-30 2004-05-18 Method for producing anhydrous eletriptan hemisulphate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0312478.1 2003-05-30
GBGB0312478.1A GB0312478D0 (en) 2003-05-30 2003-05-30 Improved process

Publications (1)

Publication Number Publication Date
WO2004106327A1 true WO2004106327A1 (en) 2004-12-09

Family

ID=9959072

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/001694 WO2004106327A1 (en) 2003-05-30 2004-05-18 Process for the preparation of anhydrous eleptritan hemisulphate

Country Status (10)

Country Link
EP (1) EP1633739A1 (en)
JP (1) JP2006528968A (en)
AR (1) AR044463A1 (en)
BR (1) BRPI0410841A (en)
CA (1) CA2527127A1 (en)
CL (1) CL2004001132A1 (en)
GB (1) GB0312478D0 (en)
MX (1) MXPA05012838A (en)
TW (1) TWI290923B (en)
WO (1) WO2004106327A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives
WO1996006842A1 (en) * 1994-08-27 1996-03-07 Pfizer Limited Salts of an anti-migraine indole derivative
WO1999001135A1 (en) * 1997-07-03 1999-01-14 Pfizer Limited Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
WO2001023377A2 (en) * 1999-09-28 2001-04-05 Pfizer Limited Polymorphic salt

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives
WO1996006842A1 (en) * 1994-08-27 1996-03-07 Pfizer Limited Salts of an anti-migraine indole derivative
WO1999001135A1 (en) * 1997-07-03 1999-01-14 Pfizer Limited Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
WO2001023377A2 (en) * 1999-09-28 2001-04-05 Pfizer Limited Polymorphic salt

Also Published As

Publication number Publication date
AR044463A1 (en) 2005-09-14
GB0312478D0 (en) 2003-07-09
CA2527127A1 (en) 2004-12-09
BRPI0410841A (en) 2006-06-27
MXPA05012838A (en) 2006-02-13
TW200427683A (en) 2004-12-16
CL2004001132A1 (en) 2005-03-18
EP1633739A1 (en) 2006-03-15
JP2006528968A (en) 2006-12-28
TWI290923B (en) 2007-12-11

Similar Documents

Publication Publication Date Title
CN110498770B (en) Method for preparing intermediate of oxaagolide
WO2010091877A2 (en) Process for producing ambrisentan
SU671728A3 (en) Method of producing derivatives of 1,2-benzisothiazoline-3 or acid-additive salts thereof
JP2018528948A (en) Novel form of apremilast and method for producing the same
JPH09323980A (en) Production of 2-(2,4-dihydroxyphenyl)-4,6-bis(2,4-dimethylphenyl)-s-triazine
US20040014983A1 (en) Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide
RU2320655C2 (en) Improved method for preparing alpha-polymorphous eletriptane bromohydrate
US7132549B2 (en) Process
US6723798B1 (en) Resins having vinyl ether linker for the solid phase organic synthesis
WO2004106327A1 (en) Process for the preparation of anhydrous eleptritan hemisulphate
NO147838B (en) INTERMEDIATE FOR USE IN PREPARATION OF THE HYPOTENSIVE AGENT 2- (4- (2-FUROYL) PIPERAZIN-1-YL) -4-AMINO-6,7-DIMETOXYKINAZOLINE
JPH0357895B2 (en)
WO1998032744A1 (en) Process for manufacturing fluconazole
JP3566297B2 (en) Improved process for producing D-(+)-biotin intermediate
US20010049445A1 (en) Process for the preparation of thiazolidinedione derivatives
JP2009526030A (en) CABERGOLINE AND METHOD FOR PRODUCING NOVEL POLYMORPHIM FORM
US5973169A (en) Ipriflavone preparation process
JP4564135B2 (en) High-purity phenothiazine compound, method for producing the same, method for producing the intermediate, and hydrate and novel crystal of the raw material for the intermediate
US6248888B1 (en) Process for the preparation of terazosin hydrochloride dihydrate
EP0279543A1 (en) Process for the preparation of an azetidine and intermediates therefor
EP0199485B1 (en) Intermediates and process
US6118006A (en) Method for preparing a tetrahydropyridin derivative
NO323827B1 (en) Process for the preparation of heterocyclic compounds
CA3226626A1 (en) Crystal form of compound represented by formula i, and preparation therefor and application thereof
KR19980031367A (en) Method for preparing amlodipine besylate

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2527127

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/012838

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2006530682

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004733602

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004733602

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0410841

Country of ref document: BR